Multiple Myeloma Clinical Trial
Beta-glucan and Fatigue in HSCT Survivors
This is a single-center, randomized, double-blind, placebo-controlled study exploring the effects of a yeast-derived Î²-glucan on clinically significant fatigue among survivors of autologous HCT due to multiple myeloma. The primary aim is to evaluate the effect of Î²-glucan supplementation on changes in fatigue symptoms, as assessed by the Brief Fatigue Inventory (BFI) global fatigue score, by testing the differences in changes in scores from baseline to the mid-point (mean of weeks 1-4) and to the end of the intervention (mean of weeks 5-8).
Fatigue is one of the most prevalent and distressing complications among hematopoietic cell transplantation HCT survivors, affecting up to 80% of patients. Fatigue has a significant negative impact on the physical, functional, social, and emotional domains of quality of life. Therefore, special attention should be directed toward therapeutic interventions in reducing persistent fatigue, which in turn improves quality of life of this patient population. Research is needed to determine if yeast-derived Î²-glucan regulates inflammatory disruption and fatigue in patient populations. This study will investigate the efficacy of Î²-glucan supplementation on fatigue symptoms in autologous HCT survivors due to multiple myeloma. The primary aim is to evaluate the effect of Î²-glucan supplementation on changes in fatigue symptoms, as assessed by the BFI global fatigue score, by testing the differences in changes in scores from baseline to the mid-point (mean of weeks 1-4) and to the end of the intervention (mean of weeks 5-8). Secondary objectives will be to evaluate tolerability, adverse events, inflammatory cytokines, quality of life, sleep disturbance, pain, anxiety, and depression.
Be â‰¥ 18 years of age.
Be an autologous HSCT survivor with clinically significant fatigue (determined post-consent). Clinically significant fatigue is defined as BFI global score greater than 3.0.
Have a medical history of the first autologous HSCT due to multiple myeloma approximately 30 days before starting the study intervention.
Be willing and able to provide written informed consent.
Be willing and able to comply with all the study-related procedures, including attending study visits for the blood draws, intake of the study supplement, and completing study questionnaires.
Have an active infection.
Have disease relapse.
Have absolute neutrophil count less than 500.
Have anemia and thrombocytopenia requiring transfusions.
Have an untreated medical condition that could clinically explain fatigue in this population (i.e., untreated hypothyroidism).
Have begun to take antidepressants less than 30 days from enrollment.
Demonstrate an inability to comply with the study and/or follow-up procedures.
Use probiotic supplements. The subjects can participate if they are willing to stop taking probiotics. A one-month withdrawal from probiotics is required
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.